Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
No drug has been FDA-approved to cure glycogen storage disease type 1a, so approved care centers on strict dietary management, including frequent feedings, uncooked or extended-release cornstarch products regulated as medical foods, and avoidance of fructose and galactose. Supportive medications such as allopurinol, ACE inhibitors, citrate, and lipid-lowering agents are used to manage complications like gout, kidney disease, and high triglycerides, while gene therapy remains investigational in clinical trials. Treatment plans vary considerably by age, liver and kidney status, and how well blood glucose is controlled, so there are several important factors to consider before assuming one approach fits everyone. See below for the full breakdown of current options, monitoring requirements, and what is still experimental.
If you or your child are experiencing symptoms like recurrent low blood sugar, an enlarged abdomen, poor growth, or unexplained fatigue, a free, instant, online symptom check can help you organize what you are noticing and understand which specialists and tests to ask about next.
Last reviewed for medical accuracy: 09/24/2026
Glycogen storage disease type 1a (GSD Ia) is a rare genetic disorder in which the body can’t properly break down stored glycogen into glucose. This results in low blood sugar (hypoglycemia) and buildup of harmful byproducts in the liver and kidneys. While GSD Ia requires lifelong management, early diagnosis and appropriate treatment can help prevent complications and support good quality of life.
There is no single “cure” for GSD Ia, but a combination of dietary, medical, and sometimes surgical approaches is approved to keep blood sugar within a safe range and manage associated metabolic disturbances.
Keeping blood sugar stable is the foundation of glycogen storage disease type 1a treatment. Key principles include:
Uncooked cornstarch is a slow-release source of glucose that has become the standard of care:
Some patients benefit from a constant supply of glucose:
Beyond glucose sources, additional treatments may be needed to manage metabolic byproducts and protect organ health:
Regular checkups are essential to adjust therapy and catch complications early:
While dietary and medical management remain the mainstays, some patients may need or consider more advanced interventions.
Experimental gene therapies aim to correct the underlying enzyme defect (glucose-6-phosphatase deficiency).
Managing glycogen storage disease type 1a is a lifelong commitment, but many people go on to lead active, fulfilling lives. Key tips include:
Even with careful management, complications can arise. Contact your healthcare team if you notice:
You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help decide if you need prompt medical attention.
This overview of glycogen storage disease type 1a treatment is intended for informational purposes only. Always speak to a doctor or metabolic specialist before making changes to your management plan. If you experience any life-threatening or serious symptoms, seek emergency care immediately.
(References)
* Kannourakis G. Glycogen storage disease. Semin Hematol. 2002 Apr;39(2):103-6. doi: 10.1053/shem.2002.31920. PMID: 11957192.
* Kishnani PS, Austin SL, Abdenur JE, Arn P, Bali DS, Boney A, Chung WK, Dagli AI, Dale D, Koeberl D, Somers MJ, Wechsler SB, Weinstein DA, Wolfsdorf JI, Watson MS, American College of Medical Genetics and Genomics. Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics. Genet Med. 2014 Nov;16(11):e1. doi: 10.1038/gim.2014.128. PMID: 25356975.
* Lee Y, Chou JY, Weinstein DA. Response letter. J Inherit Metab Dis. 2018 Nov;41(6):915. doi: 10.1007/s10545-018-0249-1. PMID: 30264173.
* Derks TGJ, Rodriguez-Buritica DF, Ahmad A, de Boer F, Couce ML, Grünert SC, Labrune P, López Maldonado N, Fischinger Moura de Souza C, Riba-Wolman R, Rossi A, Saavedra H, Gupta RN, Valayannopoulos V, Mitchell J. Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs. Nutrients. 2021 Oct 27;13(11). doi: 10.3390/nu13113828. Epub 2021 Oct 27. PMID: 34836082; PMCID: PMC8621617.
* Koeberl DD, Koch RL, Lim JA, Brooks ED, Arnson BD, Sun B, Kishnani PS. Gene therapy for glycogen storage diseases. J Inherit Metab Dis. 2024 Jan;47(1):93-118. doi: 10.1002/jimd.12654. Epub 2023 Jul 27. PMID: 37421310; PMCID: PMC10874648.
* Hannah WB, Derks TGJ, Drumm ML, Grünert SC, Kishnani PS, Vissing J. Glycogen storage diseases. Nat Rev Dis Primers. 2023 Sep 7;9(1):46. doi: 10.1038/s41572-023-00456-z. Epub 2023 Sep 7. PMID: 37679331.
* Grünert SC, Derks TGJ, Mundy H, Dalton RN, Donadieu J, Hofbauer P, Jones N, Uçar SK, LaFreniere J, Contreras EL, Pendyal S, Rossi A, Schneider B, Spiegel R, Stepien KM, Wesol-Kucharska D, Veiga-da-Cunha M, Wortmann SB. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop. Mol Genet Metab. 2024 Mar;141(3):108144. doi: 10.1016/j.ymgme.2024.108144. Epub 2024 Jan 17. PMID: 38277989.
* Kaczor M, Malicki S, Folkert J, Dobosz E, Bryzek D, Chruscicka-Smaga B, Greczan M, Wesół-Kucharska D, Piątosa B, Samborowska E, Madzio J, Książyk J, Ehmke Vel Emczyńska E, Hajdacka M, Potempa J, Młynarski W, Rokicki D, Veillard F. Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin. Blood Adv. 2024 Jun 11;8(11):2790-2802. doi: 10.1182/bloodadvances.2023012403. PMID: 38531056; PMCID: PMC11176967.
* Grünert SC, Gautschi M, Baker J, Boyer M, Burlina A, Casswall T, Corpeleijn W, Çıki K, Cotter M, Crushell E, Derks TGJ, Haas D, Kilavuz S, Kingma SDK, Korman SH, Kozek A, de Laet C, Mundy H, Nassogne MC, Quintero V, Rossi A, Spenger J, Spiegel R, Stephenne X, Stojkov D, Tal G, Veiga-da Cunha M, Wortmann SB. Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b. Mol Genet Metab. 2024 Jun;142(2):108486. doi: 10.1016/j.ymgme.2024.108486. Epub 2024 Apr 27. PMID: 38733639.
* Lan J, Zhang Y, Jin C, Chen H, Su Z, Wu J, Ma N, Zhang X, Lu Y, Chen Y, Zeng X, Zhang H, Zheng G, Sun Y, Wang C, Hu Y, Wang Y, Liu Y, Zeng Z, Shi L, He J, Cao A, Wang Y, Pan X, Jin G, Wang Y, Jiang X, Shen H, Tang Q, Xie X, Xiao Y, Zhong X, Zhang X, Zeng L, Ye L, Xie J, Geng L, Li Z, Wu X, Wang Y, Mao R, Zhang S, Huang S, Liu S, Zeng H, Xu W, Gong S, Guo Y, Yang M. Gut Dysbiosis Drives Inflammatory Bowel Disease Through the CCL4L2-VSIR Axis in Glycogen Storage Disease. Adv Sci (Weinh). 2024 Aug;11(30):e2309471. doi: 10.1002/advs.202309471. Epub 2024 Jun 18. PMID: 38889269; PMCID: PMC11321658.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.